NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. is trading at $27.26, up 1.34% on the session. The 50 day average sits at $30.91 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 36.2, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $25.74 with resistance near $28.97, so that band frames the current range. Average daily movement is roughly $1.48, or about 5.4% of the share price, which is what any stop placement has to allow for. The overall health score of 28 out of 100 combines a trend score of 25, momentum of 22 and a risk score of 42.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.